While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...